LIPID SCIENCES COMPLETES ANALYSIS OF SAFETY AND EFFECTIVENESS STUDY

Lipid Sciences has completed the data analysis phase of its HDL Therapy non-human primate safety and effectiveness study. The data showed the HDL Therapy process to be safe and well-tolerated within the study population of African green monkeys.

Lipid Sciences' HDL Therapy platform is in development as a potential treatment for atherosclerosis, a disease of blood vessels, caused by the build-up of cholesterol-filled plaques in the coronary arteries.

The study animals were monitored before, during and after each of 12 weekly infusions of plasma that was delipidated using the proprietary process and device developed by Lipid Sciences. The data included over 3,000 assays of blood chemistry and physiological variables, such as blood pressure, heart rate, temperature, and respiration rate, collected throughout the study. No significant changes in any of the monitored variables were noted during the course of the study.